ChAdOx1 nCoV-19 is a vaccine developed by Prof Sarah Gilbert of University of Oxford UK
This vaccine is currently being investigated for prophylaxis against SARS-CoV-2.
The ChAdOx1 viral vector was developed at the University of Oxford and has been investigated as a potential vector for vaccines against another human coronavirus, Middle Eastern respiratory syndrome coronavirus (MERS-CoV).
The ChAdOx1 nCoV-19 vaccine, produced in a partnership between The University of Oxford’s Jenner Institute and Italian pharmaceutical manufacturer Advent Srl, consists of an attenuated adenovirus capable of producing the spike (S) protein of SARS-CoV-2, allowing for the formation of endogenous antibodies against these proteins and, consequently, against SARS-CoV-2.
If it is successful, how much time will it take to come in the market?
Prof Gilbert is quite confident of its efficacy.
Let’s see.
it has been reported that the mass production has already started based on preliminary results of trials …human trials start tomorrow in UK … September is the date … lets c .